KEYTRUDA® (pembrolizumab) for Unresectable or Metastatic Melanoma

1 / 1
Share this content:

This slideshow reviews drug information for KEYTRUDA® (pembrolizumab), indicated for unresectable or metastatic melanoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 7: Use in Specific Populations
Slide 9: Clinical Pharmacology
Slide 13: Warnings and Precautions
Slide 15: Clinical Safety and Efficacy
Slide 20: Drug Storage and Supply Slide 22: References

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs